Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia

INTRODUCTION: Immunomodulators, including dexamethasone (DEX), have been recommended by the Infectious Disease Society of America (IDSA) to treat moderate, severe, and critical COVID-19. Tocilizumab (TCZ) was added to the treatment recommendations based on recent data from two large randomized contr...

Descripción completa

Detalles Bibliográficos
Autores principales: AlQahtani, Hajar, AlBilal, Sara, Mahmoud, Ebrahim, Aldibasi, Omar, Alharbi, Ahmad, Shamas, Nour, Alsaedy, Abdulrahman, Owaidah, Kenana, Alqahtani, Fulwah Yahya, Aleanizy, Fadilah Sfouq, Arishi, Hatim, Baharoon, Saleem, Bosaeed, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611824/
https://www.ncbi.nlm.nih.gov/pubmed/34883296
http://dx.doi.org/10.1016/j.jiph.2021.11.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611824/
https://www.ncbi.nlm.nih.gov/pubmed/34883296
http://dx.doi.org/10.1016/j.jiph.2021.11.017

Ejemplares similares